



November 6, 2014

Press release

Mitsubishi Tanabe Pharma Corporation

Supporting “good blood glucose control” in Japanese patients with diabetes joint promotion with Johnson & Johnson K.K. Medical Company

Osaka, Japan, November 6, 2014—Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka) announced today that Mitsubishi Tanabe Pharma Corporation has started jointly promoting activities supporting blood glucose control in patients with diabetes living in Japan in collaboration with Johnson & Johnson K.K. Medical Company (head office: Chiyoda-ku, Tokyo; Representative Director: Tamotsu Hiiro).

This collaboration addresses the dual aspects of pharmaceuticals and medical equipment, featuring the type 2 diabetes medications (selective DPP-4 inhibitor “Tenelia[®] 20mg tablet” and SGLT2 inhibitor “Canaglu[®] 100mg tablet”) manufactured and sold by Mitsubishi Tanabe Pharma Corporation and the self-monitoring blood glucose meter (OneTouch UltraVue[®] blood glucose meter for self-monitoring) sold by the LifeScan business group of the Johnson & Johnson K.K. Medical Company. Going forward, in order to expand awareness of the importance of realizing blood glucose control that takes into account the blood glucose patterns of each individual patient, these two companies have been cooperating in planning and distributing pamphlets for patients as well as providing information to medical practitioners through seminars and lectures. This collaboration on a nationwide scale is the first such venture for both companies.

Through this collaboration with Johnson & Johnson K.K. Medical Company, Mitsubishi Tanabe Pharma Corporation will contribute to realizing further blood glucose control in each patient with diabetes

<Contact for Inquiries>

Corporate Communications Department

Phone: +81 6-6205-5211